MX2021009500A - Anticuerpos anti-trem1 y metodos relacionados. - Google Patents

Anticuerpos anti-trem1 y metodos relacionados.

Info

Publication number
MX2021009500A
MX2021009500A MX2021009500A MX2021009500A MX2021009500A MX 2021009500 A MX2021009500 A MX 2021009500A MX 2021009500 A MX2021009500 A MX 2021009500A MX 2021009500 A MX2021009500 A MX 2021009500A MX 2021009500 A MX2021009500 A MX 2021009500A
Authority
MX
Mexico
Prior art keywords
trem1
related methods
trem1 antibodies
antibodies
methods
Prior art date
Application number
MX2021009500A
Other languages
English (en)
Inventor
Leonard G Presta
Linda Liang
Christopher Chan
Venkataraman Sriram
Aritra Pal
Tiep Tu Le
Original Assignee
Pionyr Immunotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pionyr Immunotherapeutics Inc filed Critical Pionyr Immunotherapeutics Inc
Publication of MX2021009500A publication Critical patent/MX2021009500A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Abstract

En el presente documento se proporcionan anticuerpos anti-TREM1 y métodos relacionados de fabricación y uso de anticuerpos anti-TREM1; también se proporcionan métodos y composiciones para mejorar una respuesta inmune y/o para el tratamiento de una afección relacionada con el sistema inmunitario en un individuo, por ejemplo, cáncer, que comprende destruir, inhabilitar o eliminar células mieloides no estimuladoras usando un anticuerpo anti-TREM1 o un fragmento de unión al antígeno del mismo.
MX2021009500A 2019-02-06 2020-02-06 Anticuerpos anti-trem1 y metodos relacionados. MX2021009500A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962802161P 2019-02-06 2019-02-06
US201962889994P 2019-08-21 2019-08-21
PCT/US2020/016949 WO2020163564A2 (en) 2019-02-06 2020-02-06 Anti-trem1 antibodies and related methods

Publications (1)

Publication Number Publication Date
MX2021009500A true MX2021009500A (es) 2021-09-08

Family

ID=71947128

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021009500A MX2021009500A (es) 2019-02-06 2020-02-06 Anticuerpos anti-trem1 y metodos relacionados.

Country Status (17)

Country Link
EP (1) EP3921344A4 (es)
JP (1) JP2022523145A (es)
KR (1) KR20210126638A (es)
CN (1) CN113748132A (es)
AU (1) AU2020218525A1 (es)
CA (1) CA3128053A1 (es)
CL (1) CL2021002075A1 (es)
CO (1) CO2021010887A2 (es)
CR (1) CR20210462A (es)
DO (1) DOP2021000165A (es)
IL (1) IL284818A (es)
MX (1) MX2021009500A (es)
PE (1) PE20212269A1 (es)
SG (1) SG11202108570SA (es)
TW (1) TW202037613A (es)
WO (1) WO2020163564A2 (es)
ZA (1) ZA202210284B (es)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150376294A1 (en) * 2012-12-03 2015-12-31 Rigshospitalet Anti-pad2 antibodies and treatment of autoimmune diseases
CN107580500B (zh) * 2015-02-19 2023-05-30 康姆普根有限公司 抗pvrig抗体和使用方法
WO2017127933A1 (en) * 2016-01-29 2017-08-03 The Governing Council Of The University Of Toronto Frizzled protein-binding agents and methods of use thereof
US11472877B2 (en) * 2016-03-04 2022-10-18 Alector Llc Anti-TREM1 antibodies and methods of use thereof
RU2021111187A (ru) * 2016-04-15 2021-04-29 Янссен Фармасьютикалз, Инк. Антитела против человеческого vista и их применение

Also Published As

Publication number Publication date
TW202037613A (zh) 2020-10-16
CN113748132A (zh) 2021-12-03
AU2020218525A1 (en) 2021-09-23
KR20210126638A (ko) 2021-10-20
IL284818A (en) 2021-08-31
JP2022523145A (ja) 2022-04-21
SG11202108570SA (en) 2021-09-29
WO2020163564A2 (en) 2020-08-13
CR20210462A (es) 2021-12-13
PE20212269A1 (es) 2021-11-30
DOP2021000165A (es) 2021-09-30
ZA202210284B (en) 2023-03-29
WO2020163564A3 (en) 2020-09-24
CO2021010887A2 (es) 2021-09-09
EP3921344A2 (en) 2021-12-15
CL2021002075A1 (es) 2022-04-01
EP3921344A4 (en) 2022-10-12
CA3128053A1 (en) 2020-08-13

Similar Documents

Publication Publication Date Title
PH12020550860A1 (en) Anti-trem2 antibodies and related methods
MX2021014448A (es) Modulacion de celulas mieloides estimulantes y no estimulantes.
PH12020552018A1 (en) Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
MD3353212T2 (ro) Anticorpi bispecifici anti-CD3 optimizați și utilizările acestora
ZA202005259B (en) Anti-ctla4 antibodies and methods of making and using the same
ZA201807920B (en) Anti¿gitr antibodies and uses thereof
WO2007092939A3 (en) Antigenic gm-csf peptides and antibodies to gm-csf
NZ599875A (en) Human il-23 antigen binding proteins
MX2023000738A (es) Proteinas de union a antigeno que activan el receptor de leptina.
MY194997A (en) Anti-ccr7 antibody drug conjugates
MX2020010913A (es) Anticuerpos anti-cd27 y anti-pd-l1 y constructos biespecíficos.
WO2015112749A3 (en) Methods and compositions for antibody and antibody-loaded dendritic cell mediated therapy
MX2020010104A (es) Conjugados de farmaco-anticuerpo anti-antigeno de membrana especifico de prostata (psma) humanizado.
MX2021008216A (es) Anticuerpos anti-tigit.
MX2020008718A (es) Anticuerpos de union a bcma y usos de los mismos.
MX2020001287A (es) Receptor de linfocitos t (tcrs) especificos de braf y usos de los mismos.
CR20210462A (es) Anticuerpos anti-trem1 y métodos relacionados
MX2022003191A (es) Terapias de combinacion con anticuerpos entpd2 y cd73.
MX2022003523A (es) Proteinas de union a antigenos.
HK1116198A1 (en) Antibodies binding to ephb4 for inhibiting angiogenesis and tumor growth
MX2021013532A (es) Materiales y metodos para modular la inmunidad mediada por celulas t.
MX2021001604A (es) Tratamiento del cáncer con un anticuerpo.
EA202192182A1 (ru) Антитела к trem1 и соответствующие способы
EA202091458A1 (ru) Анти-trem2 антитела и связанные с ними способы
WO2023023489A3 (en) Bispecific anti-flt3/cd3 antibodies and methods of use